January 10, 2017 / 5:58 PM / 6 months ago

BRIEF-Bristol-Myers sees operating expenses flat through 2020

1 Min Read

Jan 10 (Reuters) - Bristol-Myers Squibb Co

* Bristol-Myers Squibb CEO says expects oncology portfolio to be impacted by competition in 2017, particularly in lung cancer

* Bristol-Myers sees potential for pivotal data from 14 trials in 10 tumor types over next 24 months

* Bristol-Myers sees operating expenses remaining at 2016 level of about $9 billion through 2020

* Bristol-Myers CEO says business development remains key component of research and development strategy - JP Morgan Healthcare Conference Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below